학술논문
Vaccine-induced immune thrombotic thrombocytopenia: current evidence, potential mechanisms, clinical implications, and future directions
Document Type
Academic Journal
Author
Source
European Heart Journal Open. September 2021, Vol. 1 Issue 2
Subject
Language
English
ISSN
2752-4191
Abstract
More than a year after the onset of the COVID-19 pandemic, most of countries worldwide are still struggling with a surge of infections and thigh restrictions, as vaccination campaigns have [...]
Vaccine-induced immune thrombotic thrombocytopenia (VITT) (also termed thrombosis with thrombocytopenia syndrome or vaccine-induced thrombotic thrombocytopenia or vaccine-induced immune thrombocytopenia) is characterized by (i) venous or arterial thrombosis; (ii) mild-to-severe thrombocytopenia; (iii) positive antiplatelet factor 4 (PF4)-polyanion antibodies or anti-PF4- heparin antibodies detected by the HIT (heparin-induced thrombocytopenia) ELISA; (iv) occurring 5- 30 days after ChAdOx1 nCoV-19 (AstraZeneca) or Ad26.COV2.5 (Johnson & Johnson/Janssen) vaccination. VITT's incidence is 1 per 100 000 vaccinated people irrespective of age and up to 1 in 50 000 for people Keywords COVID-19 * Vaccine * Thrombosis * Venous thromboembolism * Cerebral sinus venous thrombosis * Thrombocytopenia vaccine-induced immune thrombotic thrombocytopenia * PF4
Vaccine-induced immune thrombotic thrombocytopenia (VITT) (also termed thrombosis with thrombocytopenia syndrome or vaccine-induced thrombotic thrombocytopenia or vaccine-induced immune thrombocytopenia) is characterized by (i) venous or arterial thrombosis; (ii) mild-to-severe thrombocytopenia; (iii) positive antiplatelet factor 4 (PF4)-polyanion antibodies or anti-PF4- heparin antibodies detected by the HIT (heparin-induced thrombocytopenia) ELISA; (iv) occurring 5- 30 days after ChAdOx1 nCoV-19 (AstraZeneca) or Ad26.COV2.5 (Johnson & Johnson/Janssen) vaccination. VITT's incidence is 1 per 100 000 vaccinated people irrespective of age and up to 1 in 50 000 for people Keywords COVID-19 * Vaccine * Thrombosis * Venous thromboembolism * Cerebral sinus venous thrombosis * Thrombocytopenia vaccine-induced immune thrombotic thrombocytopenia * PF4